본문 바로가기
KERD
논문KCI 등재

Current status of immune checkpoint inhibitors in treatment of non-small cell lung cancer

안명주|임성원
대한내과학회 (The Korean Association Of Internal Medicine)|2019.01|The Korean Journal of Internal Medicine|제34권 제1호|pp. 50-59|DOI https://doi.org/10.3904/kjim.2018.179

2

조회

0

다운로드

1

인용

0

참고문헌

키워드

ImmunotherapyCarcinomaImmune checkpoint inhibitornon-small-cell lung
주제분류내과학

초록

Lung cancer remains a leading cause of cancer mortality worldwide, including in Korea. Systemic therapy including platinum-based chemotherapy and targeted therapy should be provided to patients with stage IV non-small cell lung cancer (NSCLC). Applications of targeted therapy, such as an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) and anaplastic lymphoma kinase (ALK) inhibitors, in patients with NSCLC and an EGFR mutation or ALK gene rearrangement has enabled dramatic improvements in efficacy and tolerability. Despite advances in research and a better understanding of the molecular pathways of NSCLC, few effective therapeutic options are available for most patients with NSCLC without druggable targets, especially for patients with squamous cell NSCLC. Immune checkpoint inhibitors such as anti-cytotoxic T lymphocyte antigen- 4 or anti-programmed death-1 (PD-1) or programmed death-ligand 1 (PD-L1) have demonstrated durable response rates across a broad range of solid tumors, including NSCLC, which has revolutionized the treatment of solid tumors. Here, we review the current status and future approaches of immune checkpoint inhibitors that are being investigated for NSCLC with a focus on pembrolizumab, nivolumab, atezolizumab, durvalumab, and ipilimumab.

Abstract

Lung cancer remains a leading cause of cancer mortality worldwide, including in Korea. Systemic therapy including platinum-based chemotherapy and targeted therapy should be provided to patients with stage IV non-small cell lung cancer (NSCLC). Applications of targeted therapy, such as an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) and anaplastic lymphoma kinase (ALK) inhibitors, in patients with NSCLC and an EGFR mutation or ALK gene rearrangement has enabled dramatic improvements in efficacy and tolerability. Despite advances in research and a better understanding of the molecular pathways of NSCLC, few effective therapeutic options are available for most patients with NSCLC without druggable targets, especially for patients with squamous cell NSCLC. Immune checkpoint inhibitors such as anti-cytotoxic T lymphocyte antigen- 4 or anti-programmed death-1 (PD-1) or programmed death-ligand 1 (PD-L1) have demonstrated durable response rates across a broad range of solid tumors, including NSCLC, which has revolutionized the treatment of solid tumors. Here, we review the current status and future approaches of immune checkpoint inhibitors that are being investigated for NSCLC with a focus on pembrolizumab, nivolumab, atezolizumab, durvalumab, and ipilimumab.

참고문헌 (39)

  1. Edwards BK, "Annual report to the nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer", Cancer, 120, pp.1290~1314 (2014)
  2. Siegel RL, "Cancer statistics, 2018", CA Cancer J Clin, 68, pp.7~30 (2018)
  3. Spiro SG, "Chemotherapy versus supportive care in advanced non-small cell lung cancer : improved survival without detriment to quality of life", Thorax, 59, pp.828~836 (2004)
  4. Ardizzoni A, "Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer : an individual patient data meta-analysis", J Natl Cancer Inst, 99, pp.847~857 (2007)
  5. Scagliotti GV, "Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer", J Clin Oncol, 26, pp.3543~3551 (2008)
  6. Lindeman NI, "Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors : guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology", J Mol Diagn, 15, pp.415~453 (2013)
  7. Mok TS, "Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma", N Engl J Med, 361, pp.947~957 (2009)
  8. Fukuoka M, "Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin", paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia(IPASS), 2011, pp.29, 2866~2874
  9. Solomon BJ, "First-line crizotinib versus chemotherapy in ALK-positive lung cancer", N Engl J Med, 371, pp.2167~2177 (2014)
  10. Soria JC, "First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer(ASCEND-4) : a randomised, open-label, phase 3 study", Lancet, 389, pp.917~929 (2017)
  11. Zhou C, "Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer(OPTIMAL, CTONG-0802)", Ann Oncol, 26, pp.1877~1883 (2015)
  12. Jackman D, "Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer", J Clin Oncol, 28, pp.357~360 (2010)
  13. Stewart EL, "Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations : a review", Transl Lung Cancer Res, 4, pp.67~81 (2015)
  14. Thomas A, "Immunotherapies for non-smallcell lung cancer and mesothelioma", Lancet Oncol, 13, pp.e301~e310 (2012)
  15. Syn NL, "De-novo and acquired resistance to immune checkpoint targeting", Lancet Oncol, 18, pp.e731~e741 (2017)
  16. Brahmer JR, "Immune checkpoint inhibitors : making immunotherapy a reality for the treatment of lung cancer", Cancer Immunol Res, 1, pp.85~91 (2013)
  17. Brahmer JR, "Phase I study of single-agent anti-programmed death-1(MDX-1106)in refractory solid tumors : safety, clinical activity, pharmacodynamics, and immunologic correlates", J Clin Oncol, 28, pp.3167~3175 (2010)
  18. Patnaik A, "Phase I study of pembrolizumab(MK-3475; anti-PD-1 monoclonal antibody)in patients with advanced solid tumors", Clin Cancer Res, 21, pp.4286~4293 (2015)
  19. Herbst RS, "Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer(KEYNOTE-010) : a randomised controlled trial", Lancet, 387, pp.1540~1550 (2016)
  20. Rittmeyer A, "Atezolizumab versus docetaxel in patients with previously treated nonsmall-cell lung cancer(OAK) : a phase 3, open-label, multicentre randomised controlled trial", Lancet, 389, pp.255~265 (2017)
  21. ) vs docetaxel (DOC) in previously treated advanced or metastatic squamous (SQ) cell non-small cell lung cancer (NSCLC), "J Clin Oncol", 2015, 8009~
  22. Paz-Ares L, "Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC)", J Clin Oncol, 33(18 Suppl), pp.LBA109~ (2015)
  23. Horn L, "Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer : two-year outcomes from two randomized, open-label, phase III Trials(CheckMate 017and CheckMate 057)", J Clin Oncol, 35, pp.3924~3933 (2017)
  24. Carbone DP, "First-line nivolumab in stage IV or recurrent non-small-cell lung cancer", N Engl J Med, 376, pp.2415~2426 (2017)
  25. Reck M, "Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer", N Engl J Med, 375, pp.1823~1833 (2016)
  26. Lopes G, "Pembrolizumab (pembro)versus platinum-based chemotherapy (chemo) as firstline therapy for advanced", metastatic NSCLC with a PDL1tumor proportion score (TPS) ≥ 1%: open-label, phase 3 KEYNOTE-042 study, 2018, pp.36(18 Suppl), LBA4~
  27. Besse B, "16LBA Phase II, single-arm trial (BIRCH) of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1-selected non-small cell lung cancer (NSCLC)", Eur J Cancer, (51 Suppl 3), pp.S717~S718 (2015)
  28. Hellmann MD, "Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden", N Engl J Med, 378, pp.2093~2104 (2018)
  29. Peters S, "191TiP: MYSTIC: a global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy or durvalumab monotherapy versus platinum-based chemotherapy (CT)in the first-line treatment of patients (pts) with advanced stage IV NSCLC", J Thorac Oncol, 11(4 Suppl), pp.S139~S140 (2016)
  30. Liu WM, "Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses", Br J Cancer, 102, pp.115~123 (2010)
  31. Langer CJ, "Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer : a randomised, phase 2 cohort of the open-label KEYNOTE-021study", Lancet Oncol, 17, pp.1497~1508 (2016)
  32. Gandhi L, "Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer", N Engl J Med, 378, pp.2078~2092 (2018)
  33. Reck M, "LBA1_PR Primary PFS and safety analyses of a randomized phase III study of carboplatin + paclitaxel +", − bevacizumab, with or without atezolizumab in 1L non-squamous metastatic nsclc (IMPOWER150), 2017, pp.28(Suppl 11), mdx760.002~
  34. Lynch TJ, "Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB", IV non-small-cell lung cancer : results from a randomized, double-blind, multicenter phase II study, 2012, pp.30, 2046~2054
  35. Zhong C, "Chemotherapy plus best supportive care versus best supportive care in patients with non-small cell lung cancer : a meta-analysis of randomized controlled trials", PLoS One, 8, pp.e58466~ (2013)
  36. Paz-Ares L, "71TiP A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (EORTC", ETOP 1416-PEARLS), 2017, pp.28(Suppl 2), mdx085.013~
  37. Chaft JE, "EA5142 adjuvant nivolumab in resected lung cancers (ANVIL): the newest study in the ALCHEMIST platform", J Clin Oncol, 35(5Suppl), pp.TPS8575~ (2017)
  38. Yang CJ, "Surgical outcomes after neoadjuvant chemotherapy and ipilimumab for nonsmall cell lung cancer", Ann Thorac Surg, 105, pp.924~929 (2018)
  39. Antonia SJ, "Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer", N Engl J Med, 377, pp.1919~1929 (2017)

관련 논문AI추천

Immunotherapy for Non-small Cell Lung Cancer: Current Landscape and Future Perspectives김혜련, 임선민, Min Hee Hong대한면역학회 · Immune Network2020 · 제20권 제1호Immunotherapy for Non-small-cell Lung Cancer: Current Status and Future Obstacles조주환대한면역학회 · Immune Network2017 · 제17권 제6호Perioperative immunotherapy in stage IB-III non-small cell lung cancer: a critical review of its rationale and considerationsJae Kyeom Sim, Juwhan Choi, Sung Yong Lee대한내과학회 · The Korean Journal of Internal Medicine2023 · 제38권 제6호Updates to Clinical Information on Anticancer Immunotherapy양재욱, 최은주한국임상약학회 · 한국임상약학회지2018 · 제28권 제1호An update on immunotherapy with PD-1 and PD-L1 blockade고성애영남대학교 의과대학 · Journal of Yeungnam Medical Science2021 · 제38권 제4호Real World Experience of Nivolumab in Non-Small Cell Lung Cancer in Korea강진형, 김동완, 김봉석, 김상위, 김영철, 김주항, 나임일, 박건욱, 안명주, 안호정, 유승수, 이기형, 이성숙, 이승룡, 이종석, 이진수, 임선민, 장태원, 조병철, 조은경대한암학회 · Cancer Research and Treatment2020 · 제52권 제4호

이 간행물의 다른 논문 (27건)

Current status of acute myocardial infarction in Korea김영조, 조명찬, 김용철, 김종진, 안영근, 정명호pp. 1-10Update on heart failure management and future directions윤종찬, 박명수, 최홍미pp. 11-43Management plans for populations with normal-to-hypertensive blood pressures: risks and benefits of antihypertensive drug treatment in populations previously defined as having high-normal blood pressure박성하pp. 44-49Fecal calprotectin in daily practice for patients with inflammatory bowel disease: where do we stand in Korea?차재명pp. 60-62Microbiological and genotypic factors affecting mortality in methicillin-resistant Staphylococcus aureus bacteremia주은정pp. 63-64
원문 보기